BioPharma Updates, September 15th, 2025.
SciLeads’ BioPharma is updated daily, giving our clients the most current insights on biopharma organizations, including Funding, Initial Public Offerings, Mergers & Acquisitions, Partnerships, and more. This week’s updates are below, with links to the organizations in the platform. If you don’t have BioPharma yet, start your free trial today.
Download this update:
View BioPharma updates as a PDF.
View BioPharma updates in an Excel (.XLS) format.
Funding
- Kriya Therapeutics (NC, USA) raised $320M in Series D funding to advance clinical trials for its gene therapy pipeline in chronic diseases including geographic atrophy, thyroid eye disease, type 1 diabetes, MASH, and trigeminal neuralgia, while expanding its integrated R&D and manufacturing platform.
- Lila Sciences (MA, USA) raised $235M in Series A funding to expand its AI-driven platform that integrates generative models with autonomous labs for accelerating drug discovery and materials development, bringing the company to unicorn status.
- Odyssey Therapeutics (MA, USA) raised $213M in oversubscribed Series D funding to advance its pipeline of clinical and preclinical medicines targeting autoimmune and inflammatory diseases.
- NRG Therapeutics (Stevenage, United Kingdom) raised $67M in oversubscribed Series B funding to advance its lead program NRG5051 into clinical proof of concept for ALS/MND and generate early clinical data in Parkinson’s disease.
- CUTISS (Zurich, Switzerland) raised $63M in Series C funding to advance the Phase 3 trial and commercialization of its bio-engineered skin graft denovoSkin™, progress its automated tissue therapy platform, and prepare the launch of VitiCell®.
- Epigenic Therapeutics (Shanghai, China) raised $60M in Series B funding to advance clinical development of its epigenetic therapies, including programs for chronic hepatitis B and hypercholesterolemia, while also progressing preclinical candidates and expanding its technology platforms.
- YolTech Therapeutics (Shanghai, China) raised $45M in Series B funding to advance its in vivo genome editing programs, including therapies for ATTR, familial hypercholesterolemia, PH1, and TDT/SCD, and to expand global development efforts.
- iRegene Therapeutics (Chengdu, China) raised $40M in Series B+ funding to advance global clinical development of its iPSC-derived cell therapy NouvNeu001 for Parkinson’s disease and expand programs in retinal disorders.
- SafeHeal (Paris, France) raised $11M in Series C extension funding to advance its pivotal U.S. trial and support the EU launch of Colovac®, a device designed to avoid temporary stomas in colorectal cancer surgery.
- Madison Scientific (IL, USA) raised $10M in seed funding to advance development of its SmartShunt system, a smart electro-mechanical device designed to improve treatment and long-term care for patients with hydrocephalus and other neurologic conditions.
- Cascade Bio (CO, USA) raised $6M, combining seed funding and NSF grants, to scale its enzyme-stabilizing biocatalyst platform that extends enzyme activity and enables cost-efficient biomanufacturing.
- PeriVision (Bern, Switzerland) raised $3M in seed funding to expand its AI- and VR-based VisionOne platform for faster, more accessible eye disease diagnostics and to grow its international presence.
- NanoNewron (NJ, USA) received a $2.5M NIH STTR Phase 2 grant to advance its NN-840 program for Alzheimer’s disease, supporting IND-enabling studies ahead of a planned filing next year.
- Inkocell Therapeutics (Lausanne, Switzerland) received a $168K grant from Venture Kick to advance its next-generation NK-tailored CAR cell therapy platform aimed at developing scalable, safer, and off-the-shelf treatments for cancer and other serious diseases.
- Immix Biopharma (CA, USA) received a strategic investment from Goose Capital to advance development of its lead CAR-T program NXC-201 for relapsed/refractory AL Amyloidosis and other serious diseases.
- Valo Health (MA, USA) received an undisclosed Michael J. Fox Foundation grant to investigate NOD2 as a Parkinson’s target using human datasets and AI to determine optimal target modulation.
- Dewpoint Therapeutics (MA, USA) raised an undisclosed amount in Series D funding to advance its condensate modulator DPTX3186 into clinical trials for gastric cancer and accelerate development of additional c-mod programs.
Emerging
- Ridge Biotechnologies (CA, USA) emerged from stealth with $25M in seed funding to develop AI-enabled precision enzyme and drug design platforms, supporting next-generation antibody conjugates and enzyme-based therapeutics.
Post IPO Equity
- Avidity Biosciences (CA, USA) announced an underwritten public offering of $500M in common stock to advance late-stage clinical programs, expand commercial infrastructure, and support R&D and general corporate purposes.
- Dianthus Therapeutics (MA, USA) announced closing of a $288M underwritten public offering to advance preclinical and clinical development activities as well as for working capital and general corporate purposes.
- Rapport Therapeutics (MA, USA) announced pricing of a $250M underwritten public offering to advance its precision medicine pipeline for neurological and psychiatric disorders and for general corporate purposes.
- Amylyx Pharmaceuticals (MA, USA) announced pricing of a $175M underwritten public offering to support Avexitide commercial readiness, research and development, working capital, and general corporate purposes.
- Maze Therapeutics (CA, USA) announced pricing of an oversubscribed $150M private placement to advance kidney and metabolic disease programs, including MZE829 and MZE782, progress its Compass platform, and support general corporate purposes.
- Belite Bio (CA, USA) raised $125M in a PIPE financing to support commercialization preparation, working capital, and general corporate purposes.
- CAMP4 Therapeutics (MA, USA) announced pricing of a private placement of ~$100M to advance its SYNGAP1 program, fund R&D, and support working capital and general corporate purposes.
- Lucid Diagnostics (NY, USA) announced closing of a $28.75M underwritten public offering to support working capital and general corporate purposes.
- SELLAS Life Sciences (NY, USA) announced the immediate exercise of warrants for $23.6M in gross proceeds, with new warrants issued in a concurrent private placement.
- Sirnaomics (MD, USA) raised ~$17.7M in a strategic investment from Bloomage Biotech to accelerate development and commercialization of its aesthetics and longevity RNAi pipeline, including the STP705 fat reduction program.
- Actuate Therapeutics, Inc. (TX, USA) announced closing of a $17.25M underwritten public offering to support working capital and general corporate purposes, including a 30-day option for underwriters to purchase additional shares.
- Talphera (CA, USA) raised $17M in a private placement led by CorMedix with the potential for an additional $12M upon achieving the primary endpoint in the NEPHRO CRRT study, providing capital through the planned approval of Niyad in 2026.
- Alterity Therapeutics (Melbourne, Australia) announced pricing of a $13.2M private placement to fund non-clinical studies, CMC activities, and clinical and regulatory development of ATH434 for Multiple System Atrophy, as well as for general working capital.
- Xanadu Bio (PA, USA) raised $11M through a private stock sale to advance its PACE nanoparticle delivery platform and expand its pipeline of vaccines and tissue-targeted nucleic acid therapies.
- Revelation Biosciences Inc. (CA, USA) announced the immediate exercise of warrants for $9.6M in gross proceeds at $2.20 per share, with new Class I warrants issued in a concurrent private placement.
- Beyond Air (NY, USA) raised $3.25M through the immediate exercise of outstanding warrants to advance clinical and pre-clinical programs, operating expenses, and working capital.
- Hemostemix (Calgary, Canada) raised $280K through a non-brokered private placement to support general working capital, operational expenses, and business development activities.
Post IPO Debt
- Alnylam Pharmaceuticals (MA, USA) announced the commencement of a $500M private offering of convertible senior notes to fund capped call transactions, repurchase a portion of its 2027 notes, and for general corporate purposes.
- Celcuity (MN, USA) announced an upsized senior secured credit facility of $500M to support the rolling NDA submission and potential commercial launch of gedatolisib and other strategic initiatives.
- Serina Therapeutics, Inc. (AL, USA) secured up to $20M in multi-tranche unsecured convertible note financing, with attached warrants, to support its Phase 1b registrational study of SER-252 in advanced Parkinson’s disease.
Mergers and Acquisitions
- GTCR (IL, USA) to acquire Zentiva (Prague, Czech Republic) from Advent International for $2.3B to strengthen its position in the European generics market.
- Novartis (Basel, Switzerland) to acquire Tourmaline Bio (NY, USA) for $1.25B to strengthen its cardiovascular pipeline with pacibekitug for the treatment of atherosclerotic cardiovascular disease.
- Nestlé (Vevey, Switzerland) to acquire Seres Therapeutics (MA, USA) for $760M to expand its microbiome therapy portfolio.
- Servier (Suresnes, France) to acquire KER-0193 from Kaerus Bioscience (London, United Kingdom) for up to $450M, to advance a potential oral small-molecule treatment for Fragile X syndrome, the most common single-gene cause of autism spectrum disorder.
- Boston Scientific (MA, USA) to acquire EluPro™ and CanGaroo® bioenvelopes from Elutia (MD, USA) for $88M to expand its implantable device protection portfolio, while Elutia uses proceeds to fund development and commercialization of NXT-41 in breast reconstruction.
- FOXO Technologies, Inc. (FL, USA) to acquire Vector Biosource (MA, USA) ~$6M in cash, preferred stock, and warrants, expanding its capabilities in biospecimen sourcing and healthcare data services.
- GE HealthCare (IL, USA) to acquire Icometrix (Leuven, Belgium) to integrate its AI-powered icobrain platform with GE’s MRI systems, strengthening precision neurology solutions and advancing Alzheimer’s disease care.
Partnerships
- Samsung Biologics (Incheon, South Korea) announced a $1.3B contract manufacturing deal with an undisclosed U.S.-based pharmaceutical company running through 2029 to provide large-scale biologics production.
- Xilio Therapeutics (MA, USA) and Gilead Sciences (CA, USA) announced the initiation of a Phase 2 trial for efarindodekin alfa (XTX301) in advanced solid tumors and the achievement of a $17.5M development milestone under their license agreement.
- Remedium Bio (MA, USA) and Eli Lilly and Company (IN, USA) announced a multi-target R&D collaboration to develop gene therapies for Type 2 diabetes and obesity using Remedium’s Prometheus™ platform, with Remedium receiving upfront, equity, milestone payments, and royalties on sales.
- AMO Pharma (Leeds, United Kingdom) and Population Health Research Institute (Hamilton, Canada) announced a license agreement to advance AMO-02 for arrhythmogenic right ventricular cardiomyopathy, with a 120-patient Phase 2 proof-of-concept trial now underway across 17 sites in Canada.
- KBI Biopharma (NC, USA) and Infinimmune (CA, USA) announced a collaboration to advance manufacturing of IFX-101, Infinimmune’s lead human monoclonal antibody for atopic dermatitis, leveraging KBI’s SUREmAb™ platform and Infinimmune’s GLIMPSE™ and Anthrobody® technologies.
- Tolerance Bio (PA, USA) and ZipCode Bio (MA, USA) announced a strategic R&D collaboration to develop thymus-targeting RNA therapeutics for immune aging and autoimmunity, combining ZipCode’s SHARP delivery technology with Tolerance Bio’s expertise in thymus biology.
- Kytopen (MA, USA) and BlueWhale Bio (PA, USA) announced a collaboration to develop a non-viral cell therapy manufacturing workflow combining Flowfect® and Synecta™ technologies to accelerate and scale personalized cell therapies.
- VolitionRx (NV, USA) and Werfen (Spain) announced a research license and exclusive commercial option agreement to evaluate and potentially commercialize the Nu.Q® NETs assay for Antiphospholipid Syndrome (APS).
- Promega (WI, USA) and Watchmaker Genomics (CO, USA) announced a strategic partnership to license a novel engineered reverse transcriptase to enhance RNA analysis accuracy and sensitivity for clinical, applied, and pharmaceutical applications.
- Evonik (Essen, Germany) and Ethris (Planegg, Germany) announced a strategic collaboration to develop and market a novel SNaP LNP® delivery platform, expanding Evonik’s CDMO services and advancing RNA-based therapeutics and vaccines.
- Circle Pharma, Inc. (CA, USA) and Eli Lilly and Company (IN, USA) announced a collaboration enabling Circle to use Lilly’s AI/ML TuneLab platform to advance its MXMO™ macrocycle drug discovery platform and oncology pipeline.
- VedaBio (CA, USA) and Mammoth Biosciences (CA, USA) announced a non-exclusive license agreement granting VedaBio access to CRISPR technologies to accelerate development of next-generation diagnostic solutions.
- NeuraLight (Tel Aviv, Israel) and CHDI Foundation (NY, USA) announced a collaboration to develop novel, sensitive biomarkers for Huntington’s disease clinical trials using NeuraLight’s eye movement data capture platform.
- Scipher Medicine (MA, USA) and Maxymune Therapeutics (CA, USA) announced a strategic collaboration to leverage Scipher’s AI-driven precision immunology platform for target ranking and validation in autoimmune and inflammatory diseases.
- Marius Pharmaceuticals (NC, USA) and Hims & Hers (CA, USA) announced a collaboration to make KYZATREX®, the first FDA-approved oral testosterone therapy, available through the Hims & Hers digital health platform.
- Ignite Proteomics (CO, USA) and Inova Health (VA, USA) announced a research collaboration to apply Reverse Phase Protein Array technology in gastrointestinal cancers, enabling functional proteomics data to guide precision oncology treatment decisions.
- Medicines Discovery Catapult (United Kingdom) and Crown Bioscience (CA, USA) announced a strategic global collaboration to deliver an integrated translational biology platform for radiopharmaceutical development, combining radiochemistry, imaging, and preclinical oncology expertise to accelerate novel cancer therapies.
- Kashiv BioSciences (NJ, USA) and CRISTÁLIA (Sao Paolo, Brazil) announced a licensing and supply agreement for the commercialization of ADL-018, a proposed Xolair® biosimilar, across Latin America.
- N-Power Medicine, Inc. (CA, USA) and VieCure (CO, USA) announced a strategic partnership to integrate the Kaleido Registry™ with the Halo Intelligence Platform, expanding clinical trial access and precision medicine insights in community oncology practices.
- Cellectar Biosciences (NJ, USA) and ITM Isotope Technologies Munich (Germany) announced a supply agreement for Actinium-225 to support the clinical development of Cellectar’s actinium-labeled radiopharmaceutical candidates, including CLR 121225 for solid tumors.
- Recipharm (Stockholm, Sweden) and NeuroSense Therapeutics (MA, USA) announced a partnership to develop and manufacture PrimeC, a fixed-dose ALS therapy, overcoming complex formulation challenges to support late-stage clinical trials and future commercialization.
- INBRAIN Neuroelectronics (Barcelona, Spain) and Mayo Clinic (NY, USA) announced a collaboration to accelerate clinical evaluation and commercialization of INBRAIN’s graphene-based BCI-Tx platform for neurological disorders.
Initial Public Offering (IPO)
- LB Pharmaceuticals (NY, USA) announced pricing of its upsized $285M initial public offering to advance development of its neuropsychiatric disease pipeline and support general corporate purposes.
Registered Direct Offering (RDO)
- Cocrystal Pharma, Inc. (WA, USA) announced ~$13M registered direct offering priced at-the-market under Nasdaq rules, including $4.7M upfront and up to $8.3M from warrant exercises, to support working capital and general corporate purposes.
- Citius Oncology, Inc. (NJ, USA) announced closing of a $9M registered direct offering with concurrent private placement of warrants to support its oncology portfolio and general corporate purposes.
Closures and Layoffs
- Lundbeck (Copenhagen, Denmark) to lay off 602 employees as part of a resource reallocation strategy and exit from 27 markets.
- Novo Nordisk (Ballerup, Denmark) is laying off roughly 9,000 employees, including 5,000 in Denmark, to save around $1.3 billion annually by the end of 2026.
Is there anything else you’d love to see here or have added to the platform? Please don’t hesitate to contact us with your feedback.